DICE Therapeutics (NASDAQ:DICE – Get Rating) is one of 950 public companies in the "Pharmaceutical preparations" industry, but how does it contrast to its peers? We will compare DICE Therapeutics to similar businesses based on the strength of its risk, institutional ownership, earnings, analyst recommendations, valuation, profitability and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for DICE Therapeutics and its peers, as provided by MarketBeat.

DICE Therapeutics currently has a consensus price target of $43.33, suggesting a potential upside of 116.88%. As a group, "Pharmaceutical preparations" companies have a potential upside of 95.82%. Given DICE Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe DICE Therapeutics is more favorable than its peers.

Valuation and Earnings

DICE Therapeutics' peers have higher revenue and earnings than DICE Therapeutics. DICE Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares DICE Therapeutics and its peers' net margins, return on equity and return on assets.

Institutional & Insider Ownership

95.4% of DICE Therapeutics shares are owned by institutional investors. Comparatively, 42.3% of shares of all "Pharmaceutical preparations" companies are owned by institutional investors. 4.3% of DICE Therapeutics shares are owned by insiders. Comparatively, 15.0% of shares of all "Pharmaceutical preparations" companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

DICE Therapeutics beats its peers on 7 of the 12 factors compared.

DICE Therapeutics Company Profile

(Get Rating)

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.